BrYet Develops Approach Targeting Cancer-Specific Phenotypes to Outpace Tumor Evolution

Biotech company BrYet is pursuing a new strategy to treat metastatic cancer by targeting cancer-specific phenotypes rather than genetic mutations. The approach is designed to address the fundamental challenge of genetic instability, which makes metastatic cancer largely incurable and allows tumors to evolve resistance to existing therapies.

The core problem is that cancer cells accumulate genetic changes rapidly, enabling them to evade drugs that target specific mutations. BrYet aims to work around this instability by focusing on phenotypic traits that are unique to cancer cells and are less likely to change as the tumor evolves. By targeting these stable, cancer-specific features, the company hopes to stay ahead of the disease's evolutionary adaptation.

BrYet's research is still in development, and the company has not yet released clinical data. The approach represents a conceptual shift from mutation-based precision medicine to a broader phenotype-based strategy.

Why this matters for life sciences: Cancer evolution is a major obstacle in oncology, particularly for late-stage metastatic disease where tumors have already spread and diversified. Most targeted therapies fail because cancer cells mutate around the drug's target. If BrYet's phenotype-based approach proves effective, it could offer a new framework for developing treatments that are less vulnerable to resistance. The concept also has implications for other areas of life sciences, such as infectious disease and antimicrobial resistance, where pathogens similarly evolve to evade treatment. A strategy that targets stable phenotypic traits could be applied beyond oncology to combat drug resistance more broadly.

Source: original report